Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation

NCT00494871 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00494871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00494871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
January 31, 2010
Enrollment
1,280 (actual)
Sites
165

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation